Long-term impact of palovarotene treatment on HO volume in patients with FOP: Data from the Phase III MOVE Trial
By: Edward Hsiao, MD, PhD
University of California, San Francisco
Validation of quantitative [18F]NaF PET uptake parameters in bone diseases: A systematic review
By: Jolien Zwama, MSc
Amsterdam University Medical Center
Characterization of flare-ups and impact of garetosmab in adults with FOP: A post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 Trial
By: Robert Sanchez, PhD
Regeneron Pharmaceuticals
Qualitative patient interviews to characterize the flares experience within the FOP population
By: Robert Sanchez, PhD
Regeneron Pharmaceuticals
ANDECAL, A Phase 2/3 study to determine the efficacy of the MMP9-inhibitor andecaliximab to block new HO in FOP: Methodology for Part 1 of the Study
By: Deborah Wenkert, MD
āshibio
Tofacitinib in the treatment of FOP: Single center experience of drug reposition from rheumatology practice
By: Irina Nikishina, MD, PhD
V.A. Nasonova Research Institute of Rheumatology
PI3K inhibition restores proper intercellular communication at injury sites
By: Francesc Ventura Pujol, PhD
University of Barcelona
Characterising approved and investigational ACVR1 kinase inhibitors
By: Will Seaton-Burn, MSc
University of Oxford
Chemical modifications leading to highly selective ACVR1 kinase inhibitors
By: Julien Cros, PhD
University of Oxford
Allele-specific antisense oligonucleotides as a therapeutic approach for the treatment of FOP
By: Rika Maruyama, PhD
University of Alberta
A novel strategy for targeting mutant ACVR1 with therapeutic small interfering RNAs
By: David Cooper, BSc
University of Massachusetts Chan Medical School
Development of a combinatorial siRNA therapy for the treatment of FOP
By: Katherine Gross, BSc
University of Massachusetts Chan Medical School
Long-term use of interleukin-1 inhibitors reduce flare activity in patients with FOP
By: Ruby Haviv, MD
Meir Medical Center
Interleukin 1 receptor antagonist as biomarker for disease flares in FOP
By: Riccardo Papa, MD, PhD
IRCCS Istituto Giannina Gaslnii
Describing the clinical characteristics of patients living with FOP: a non-interventional cohort in the USA
By: Caitlin Knox, PhD, MPH
Regeneron Pharmaceuticals
Epidemiology of FOP mortality in the USA, 2017-2023
By: Caitlin Knox, PhD, MPH
Regeneron Pharmaceuticals
A retrospective analysis of the clinical burden of FOP utilizing matched patient data
By: Jeanna Cooper, Pharm.D
IPSEN
Access to clinical trials for FOP: The role of comprehensive outreach strategies
By: Chris Scott, MBChB, FCPaed(SA)Grad Cert Paed Rheum(UWA)
Children's Hospital of Eastern Ontario and University of Ottawa
Expression analysis of microRNA in peripheral blood monocyte cells derived from patients with FOP
By: Alberto Hidalgo-Bravo, MD, PhD
Instituto Nacional de Rehabilitación
A novel gain-of-function mutation in BMPR2 in a patient with variant FOP
By: Yonghwan Kim, PhD
Sookmyung Women's University
Abnormal TGF-β signaling activation by intrinsic BMP-9 mediates fibroproliferation in FOP
By: Makoto Ikeya, PhD
Kyoto University
Computational studies followed by directed mutagenesis of ALK2-R206H show the resemblance of wild-type like conditions in ALK2-R206H double-mutants
By: Leon Obendorf, MSc
Freie Universität Berlin
Novel ACVR1 Variant p.L184S imparts activin responsiveness
By: Lap Hang Tse, PhD
University of Oxford
TGF-Beta induces Activin A production in dermal fibroblasts derived from patients with FOP
By: Dimitra Micha, PhD
Amsterdam University Medical Center
iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces HO in a mouse model of FOP
By: Pan Gao, PhD
Sichuan University